Mecnanism of Action
GLP-1R:
Slows gastric emptying, enhances satiety,and reduces appetite.
GIPR:
Regulates hunger signals in the centralnervous system, further suppresses appetiteand improves energy metabolism.
GCGR:
Promotes glucagon secretion, acceleratesfat and glycogenolysis, and increases basalmetabolic rate.
which it is capable.
Indications and Efficacy
Obesity Treatment:
In the Phase II clinical trial, patients in the highest dosegroup (12 mg) lost an average of 24.2% weight after48 weeks, and some patients lost more than 30%.
Metabolic Dysfunction-AssociatedFatty Liver Disease (MASLD):
Retatrutide can reduce liver fat content by 86% and morethan 85% of patients achieve regression of liver steatosis.
Retatrutide can reduce liver fat content by 86% and morethan 85% of patients achieve regression of liver steatosis.
Type II Diabetes:
Significantly reduce glycated hemoglobin(HbAlc) andimprove blood sugar control.
Potential Cardiovascular Benefits:
Animal studies have shown that it may indirectly protectcardiovascular health by improving blood pressure andheart function, but further clinical verification is needed.
Animal studies have shown that it may indirectly protectcardiovascular health by improving blood pressure andheart function, but further clinical verification is needed.
